靶向白细胞介素23通路在炎症性肠病中的研究
综述阐述白细胞介素23(IL23)的p19与p40亚基结构及其在炎症性肠病(IBD)发病中的作用,讨论IL23p19抑制剂的药效学与药代动力学、作用机制、表位亲和力与下游信号,汇总其治疗IBD的疗效、安全性与耐受性数据,并探讨联合生物治疗及精准医学指导下的定位。
要点
- IL23是由二硫键连接的p19和p40亚基组成的异二聚体,参与维持肠道稳态并与IBD发病相关。
- 选择性靶向IL23 p19亚基的人源化单克隆抗体有望成为IBD的重要药物。
- 综述汇总IL23p19抑制剂治疗IBD的疗效、安全性与耐受性数据,并讨论联合生物治疗及精准医学定位。
核心结论
- 选择性靶向IL23 p19亚基的人源化单克隆抗体有望成为炎症性肠病的重要药物。
研究设计与样本
- 综述,讨论目前可用的IL23p19抑制剂的药效学与药代动力学特性及其治疗效应的机制基础。
- 综述汇总IL23p19抑制剂治疗炎症性肠病的疗效、安全性与耐受性数据,并纳入其他免疫介导炎症性疾病的重要研究。
主要发现
- IL23是IL12家族细胞因子成员,为二硫键连接的p19和p40亚基组成的异二聚体,维持肠道稳态,也参与炎症性肠病发病。
- 综述讨论IL23p19抑制剂的作用机制、表位亲和力、效力及下游信号。
- 综述评估联合不同类别生物治疗的潜力,并提出精准医学指导IL23p19抑制剂在炎症性肠病中定位的未来方向。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Interleukin (IL) 23, a member of the IL12 family of cytokines, maintains intestinal homeostasis, but is also implicated in the pathogenesis of inflammatory bowel diseases (IBDs). IL23 is a heterodimer composed of disulfide-linked p19 and p40 subunits. Humanized monoclonal antibodies selectively targeting the p19 subunit of IL23 are poised to become prominent drugs in IBDs. In this review, we discuss the pharmacodynamic and pharmacokinetic properties of the currently available IL23p19 inhibitors and discuss the mechanistic underpinnings of their therapeutic effects, including the mechanism of action, epitope affinity, potency, and downstream signaling. Furthermore, we address available data on the efficacy, safety, and tolerability of IL23p19 inhibitors in the treatment of IBDs and discuss important studies performed in other immune-mediated inflammatory diseases. Finally, we evaluate the potential for combining classes of biological therapies and provide future directions on the development of precision medicine-guided positioning of IL23p19 inhibitors in IBD.
引用
- Bourgonje AR, Ungaro RC, Mehandru S, et al. Targeting the Interleukin 23 Pathway in Inflammatory Bowel Disease. Gastroenterology. 2024. PMID: 38945499. doi:10.1053/j.gastro.2024.05.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。